Glaxo CEO tells Reuters likely to resume share buybacks

Reuters subscribers got exclusive news on Dec. 13 that GlaxoSmithKline was likely to resume buying back shares, via an interview with the CEO of Britains biggest drugmaker at the Reuters London office. Andrew Witty said a return to buybacks was on the cards because of the lack of good acquisition opportunities. His comments prompted numerous calls to the companys investor relations department from analysts seeking more information. The remarks were also picked up in a note from brokerage Jefferies and reproduced in the Daily Mail newspaper.